Skip to main content
  • Register
  • Help
  • Contact us

Kindred Biosciences Inc (KIN) USD0.0001

Sell:$4.45 Buy:$4.79 Change: $0.01 (0.22%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$4.45
Buy:$4.79
Change: $0.01 (0.22%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$4.45
Buy:$4.79
Change: $0.01 (0.22%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

Contact details

Address:
1555 Bayshore Hwy Ste 200
BURLINGAME
94010-1617
United States
Telephone:
+1 (650) 7017901
Website:
https://kindredbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KIN
ISIN:
US4945771099
Market cap:
$210.52 million
Shares in issue:
45.27 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Richard Chin
    President, Chief Executive Officer, Director
  • Wendy Wee
    Chief Financial Officer, Secretary
  • Hangjun Zhan
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.